{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T10:35:58Z","timestamp":1794566158185,"version":"4.9.1"},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T00:00:00Z","timestamp":1618358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Trial enrichment using gut microbiota derived biomarkers by high-risk individuals can improve the feasibility of randomized controlled trials for prevention of <jats:italic>Clostridioides difficile<\/jats:italic> infection (CDI). Here, we report in a prospective observational cohort study the incidence of CDI and assess potential clinical characteristics and biomarkers to predict CDI in 1,007 patients \u2265 50 years receiving newly initiated antibiotic treatment with penicillins plus a beta-lactamase inhibitor, 3<jats:sup>rd<\/jats:sup>\/4<jats:sup>th<\/jats:sup> generation cephalosporins, carbapenems, fluoroquinolones or clindamycin from 34 European hospitals. The estimated 90-day cumulative incidences of a first CDI episode is 1.9% (95% CI 1.1-3.0). Carbapenem treatment (Hazard Ratio (95% CI): 5.3 (1.7-16.6)), toxigenic <jats:italic>C. difficile<\/jats:italic> rectal carriage (10.3 (3.2-33.1)), high intestinal abundance of <jats:italic>Enterococcus<\/jats:italic> spp. relative to <jats:italic>Ruminococcus<\/jats:italic> spp. (5.4 (2.1-18.7)), and low Shannon alpha diversity index as determined by 16\u2009S rRNA gene profiling (9.7 (3.2-29.7)), but not normalized urinary 3-indoxyl sulfate levels, predicts an increased CDI risk.<\/jats:p>","DOI":"10.1038\/s41467-021-22269-y","type":"journal-article","created":{"date-parts":[[2021,4,14]],"date-time":"2021-04-14T10:05:44Z","timestamp":1618394744000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Incidence and predictive biomarkers of Clostridioides difficile infection in hospitalized patients receiving broad-spectrum antibiotics"],"prefix":"10.1038","volume":"12","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0626-4635","authenticated-orcid":false,"given":"Cornelis H.","family":"van Werkhoven","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annie","family":"Ducher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7096-7896","authenticated-orcid":false,"given":"Matilda","family":"Berkell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5746-4330","authenticated-orcid":false,"given":"Mohamed","family":"Mysara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Lammens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1529-6302","authenticated-orcid":false,"given":"Julian","family":"Torre-Cisneros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6732-9001","authenticated-orcid":false,"given":"Jes\u00fas","family":"Rodr\u00edguez-Ba\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Delia","family":"Herghea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9599-3137","authenticated-orcid":false,"given":"Oliver A.","family":"Cornely","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena M.","family":"Biehl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louis","family":"Bernard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Angeles","family":"Dominguez-Luzon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0945-1732","authenticated-orcid":false,"given":"Sofia","family":"Maraki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2015-9206","authenticated-orcid":false,"given":"Olivier","family":"Barraud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Nica","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathalie","family":"Jazmati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederique","family":"Sablier-Gallis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8049-9283","authenticated-orcid":false,"given":"Jean","family":"de Gunzburg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Mentr\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8699-8905","authenticated-orcid":false,"given":"Surbhi","family":"Malhotra-Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc J. M.","family":"Bonten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0446-3224","authenticated-orcid":false,"given":"Maria J. G. T.","family":"Vehreschild","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the ANTICIPATE Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annemarie M. S.","family":"Engbers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke J. A.","family":"de Regt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Herman","family":"Goossens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Basil Britto","family":"Xavier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie-Noelle","family":"Bouverne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter","family":"Monsieurs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uta","family":"Merle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Stallmach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"Rupp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johannes","family":"Bogner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christoph","family":"L\u00fcbbert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerda","family":"Silling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oliver","family":"Witzke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Achilleas","family":"Gikas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Daikos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sotirios","family":"Tsiodras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athanasios","family":"Skoutelis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Sambatakou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miquel","family":"Pujol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose M.","family":"Aguado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilio","family":"Bouza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Cobo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benito","family":"Almirante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simin A.","family":"Florescu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrei","family":"Vata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriana","family":"Hristea","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mihaela","family":"Lupse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah","family":"Postil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoire","family":"De Lastours","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Guimard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Philippe","family":"Talarmin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xavier","family":"Duval","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Odile","family":"Launay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,4,14]]},"reference":[{"key":"22269_CR1","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1056\/NEJMoa1408913","volume":"372","author":"FC Lessa","year":"2015","unstructured":"Lessa, F. C. et al. Burden of Clostridium difficile infection in the United States. N. Engl. J. Med. 372, 825\u2013834 (2015).","journal-title":"N. Engl. J. Med."},{"key":"22269_CR2","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1093\/cid\/cix1021","volume":"66","author":"D Zhang","year":"2018","unstructured":"Zhang, D., Prabhu, V. S. & Marcella, S. W. Attributable healthcare resource utilization and costs for patients with primary and recurrent Clostridium difficile Infection in the United States. Clin. Infect. Dis. 66, 1326\u20131332 (2018).","journal-title":"Clin. Infect. Dis."},{"key":"22269_CR3","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/j.medmal.2017.10.010","volume":"48","author":"SM Heimann","year":"2018","unstructured":"Heimann, S. M., Cruz Aguilar, M. R., Mellinghof, S. & Vehreschild, M. J. G. T. Economic burden and cost-effective management of Clostridium difficile infections. Med. Mal. Infect. 48, 23\u201329 (2018).","journal-title":"Med. Mal. Infect."},{"key":"22269_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1017\/ice.2018.84","volume":"39","author":"BC Johnston","year":"2018","unstructured":"Johnston, B. C. et al. Microbial preparations (Probiotics) for the prevention of Clostridium difficile infection in adults and children: an individual patient data meta-analysis of 6,851 participants. Infect. Control Hosp. Epidemiol. 39, 771\u2013781 (2018).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"22269_CR5","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1093\/infdis\/jix604","volume":"217","author":"Jde Gunzburg","year":"2018","unstructured":"Gunzburg, Jde et al. Protection of the human gut microbiome from antibiotics. J. Infect. Dis. 217, 628\u2013636 (2018).","journal-title":"J. Infect. Dis."},{"key":"22269_CR6","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1016\/S1473-3099(18)30731-X","volume":"19","author":"JF Kokai-Kun","year":"2019","unstructured":"Kokai-Kun, J. F. et al. Use of ribaxamase (SYN-004), a \u03b2-lactamase, to prevent Clostridium difficile infection in \u03b2-lactam-treated patients: a double-blind, phase 2b, randomised placebo-controlled trial. Lancet Infect. Dis. 19, 487\u2013496 (2019).","journal-title":"Lancet Infect. Dis."},{"key":"22269_CR7","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.vaccine.2016.03.098","volume":"34","author":"N B\u00e9zay","year":"2016","unstructured":"B\u00e9zay, N. et al. Safety, immunogenicity and dose response of VLA84, a new vaccine candidate against Clostridium difficile, in healthy volunteers. Vaccine 34, 2585\u20132592 (2016).","journal-title":"Vaccine"},{"key":"22269_CR8","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1016\/S0140-6736(13)61218-0","volume":"382","author":"SJ Allen","year":"2013","unstructured":"Allen, S. J. et al. Lactobacilli and bifidobacteria in the prevention of antibiotic-associated diarrhea and Clostridium difficile diarrhea in older inpatients (PLACIDE): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet 382, 1249\u20131257 (2013).","journal-title":"Lancet"},{"key":"22269_CR9","doi-asserted-by":"publisher","first-page":"010417","DOI":"10.7189\/jogh.07.010417","volume":"7","author":"P Eze","year":"2017","unstructured":"Eze, P., Balsells, E., Kyaw, M. H. & Nair, H. Risk factors for Clostridium difficile infections\u2014an overview of the evidence base and challenges in data synthesis. J. Glob. Health 7, 010417 (2017).","journal-title":"J. Glob. Health"},{"key":"22269_CR10","first-page":"1193","volume":"72","author":"K Kavanagh","year":"2017","unstructured":"Kavanagh, K. et al. Cumulative and temporal associations between antimicrobial prescribing and community-associated Clostridium difficile infection: population-based case\u2013control study using administrative data. J. Antimicrob. Chemother. 72, 1193\u20131201 (2017).","journal-title":"J. Antimicrob. Chemother."},{"key":"22269_CR11","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/ajg.2015.22","volume":"110","author":"IM Zacharioudakis","year":"2015","unstructured":"Zacharioudakis, I. M., Zervou, F. N., Pliakos, E. E., Ziakas, P. D. & Mylonakis, E. Colonization with toxinogenic C. difficile upon hospital admission, and risk of infection: a systematic review and meta-analysis. Am. J. Gastroenterol. 110, 381\u2013390 (2015).","journal-title":"Am. J. Gastroenterol."},{"key":"22269_CR12","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1038\/nature13828","volume":"517","author":"CG Buffie","year":"2015","unstructured":"Buffie, C. G. et al. Precision microbiome reconstitution restores bile acid mediated resistance to Clostridium difficile. Nature 517, 205\u2013208 (2015).","journal-title":"Nature"},{"key":"22269_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.ejim.2018.02.006","volume":"50","author":"M Samarkos","year":"2018","unstructured":"Samarkos, M., Mastrogianni, E. & Kampouropoulou, O. The role of gut microbiota in Clostridium difficile infection. Eur. J. Intern. Med. 50, 28\u201332 (2018).","journal-title":"Eur. J. Intern. Med."},{"key":"22269_CR14","doi-asserted-by":"publisher","unstructured":"Berkell, M., et al. Microbiota-based markers predictive of development of Clostridioides difficile infection. Nat. Commun. https:\/\/doi.org\/10.1038\/s41467-021-22302-0 (2021).","DOI":"10.1038\/s41467-021-22302-0"},{"key":"22269_CR15","doi-asserted-by":"publisher","first-page":"786.e1","DOI":"10.1016\/j.cmi.2015.04.005","volume":"21","author":"CHvan Werkhoven","year":"2015","unstructured":"Werkhoven, C. Hvan et al. Identification of patients at high risk for Clostridium difficile infection: development and validation of a risk prediction model in hospitalized patients treated with antibiotics. Clin. Microbiol. Infect. 21, 786.e1\u20138 (2015).","journal-title":"Clin. Microbiol. Infect."},{"key":"22269_CR16","doi-asserted-by":"publisher","first-page":"1723","DOI":"10.1182\/blood-2015-04-638858","volume":"126","author":"D Weber","year":"2015","unstructured":"Weber, D. et al. Low urinary indoxyl sulfate levels early after transplantation reflect a disrupted microbiome and are associated with poor outcome. Blood 126, 1723\u20131728 (2015).","journal-title":"Blood"},{"key":"22269_CR17","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1080\/19490976.2018.1502536","volume":"10","author":"F Farowski","year":"2019","unstructured":"Farowski, F. et al. Assessment of urinary 3-indoxyl sulfate as a marker for gut microbiota diversity and abundance of Clostridiales. Gut Microbes 10, 133\u2013141 (2019).","journal-title":"Gut Microbes"},{"key":"22269_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/2049-2618-1-18","volume":"1","author":"C Vincent","year":"2013","unstructured":"Vincent, C. et al. Reductions in intestinal Clostridiales precede the development of nosocomial Clostridium difficile infection. Microbiome 1, 18 (2013).","journal-title":"Microbiome"},{"key":"22269_CR19","doi-asserted-by":"publisher","first-page":"2884","DOI":"10.1128\/JCM.00845-13","volume":"51","author":"VC Antharam","year":"2013","unstructured":"Antharam, V. C. et al. Intestinal dysbiosis and depletion of butyrogenic bacteria in Clostridium difficile infection and nosocomial diarrhea. J. Clin. Microbiol. 51, 2884\u20132892 (2013).","journal-title":"J. Clin. Microbiol."},{"key":"22269_CR20","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1007\/s10096-013-1966-x","volume":"33","author":"E Goldberg","year":"2014","unstructured":"Goldberg, E. et al. The correlation between Clostridium-difficile infection and human gut concentrations of Bacteroidetes phylum and clostridial species. Eur. J. Clin. Microbiol. Infect. Dis. 33, 377\u2013383 (2014).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"22269_CR21","doi-asserted-by":"publisher","DOI":"10.1186\/s40168-016-0156-3","volume":"4","author":"C Vincent","year":"2016","unstructured":"Vincent, C. et al. Bloom and bust: intestinal microbiota dynamics in response to hospital exposures and Clostridium difficile colonization or infection. Microbiome 4, 12 (2016).","journal-title":"Microbiome"},{"key":"22269_CR22","doi-asserted-by":"publisher","first-page":"e00426","DOI":"10.1128\/JCM.00426-18","volume":"56","author":"N Jazmati","year":"2018","unstructured":"Jazmati, N. et al. Evaluation of the use of rectal swabs for laboratory diagnosis of Clostridium difficile infection. J. Clin. Microbiol. 56, e00426\u201318 (2018).","journal-title":"J. Clin. Microbiol"},{"key":"22269_CR23","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1016\/j.cmi.2019.02.002","volume":"25","author":"E Melzer","year":"2019","unstructured":"Melzer, E. et al. Universal screening for Clostridioides difficile in a tertiary hospital: risk factors for carriage and clinical disease. Clin. Microbiol. Infect. 25, 1127\u20131132 (2019).","journal-title":"Clin. Microbiol. Infect."},{"issue":"Suppl 4","key":"22269_CR24","doi-asserted-by":"publisher","first-page":"S63","DOI":"10.1016\/j.cmi.2016.03.010","volume":"22","author":"MJT Crobach","year":"2016","unstructured":"Crobach, M. J. T. et al. European Society of Clinical Microbiology and Infectious Diseases: update of the diagnostic guidance document for Clostridium difficile infection. Clin. Microbiol Infect. 22(Suppl 4), S63\u2013S81 (2016).","journal-title":"Clin. Microbiol Infect."},{"key":"22269_CR25","unstructured":"R Core Team (2018). R: A language and environment for statistical computing. (R Foundation for Statistical Computing, Vienna, Austria). https:\/\/www.R-project.org\/."},{"key":"22269_CR26","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.1093\/femsec\/fix029","volume":"93","author":"M Mysara","year":"2017","unstructured":"Mysara, M. et al. Reconciliation between operational taxonomic units and species boundaries. FEMS Microbiol. Ecol. 93, e1\u2013e12 (2017).","journal-title":"FEMS Microbiol. Ecol."},{"key":"22269_CR27","unstructured":"Bob Gray (2014). cmprsk: Subdistribution Analysis of Competing Risks. R package version 2.2-7. https:\/\/CRAN.R-project.org\/package=cmprsk"},{"key":"22269_CR28","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","volume":"94","author":"JP Fine","year":"1999","unstructured":"Fine, J. P. & Gray, R. J. A proportional hazards model for the subdistribution of a competing risk. J. Am. Stat. Assoc. 94, 496\u2013509 (1999).","journal-title":"J. Am. Stat. Assoc."},{"key":"22269_CR29","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1002\/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3","volume":"3","author":"WJ Youden","year":"1950","unstructured":"Youden, W. J. Index for rating diagnostic tests. Cancer 3, 32\u201335 (1950).","journal-title":"Cancer"}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22269-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22269-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22269-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T11:58:38Z","timestamp":1669982318000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-021-22269-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,14]]},"references-count":29,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["22269"],"URL":"https:\/\/doi.org\/10.1038\/s41467-021-22269-y","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,14]]},"assertion":[{"value":"11 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 April 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.Hv.W. received speaker fees from Pfizer and Merck\/MSD, and non-financial research support from bioM\u00e9rieux. A.D. and F.S. are employees and shareholders of Da Volterra, Paris. J.G. is a consultant and shareholder of Da Volterra. J.T.C. has received speaker and consultant fess from Pfizer, MSD, Shionogy, Menarini and research support from Pfizer. O.A.C. is supported by the German Federal Ministry of Research and Education, is funded by the Deutsche Forschungsgemeinschaft (DFG, German Research Foundation) under Germany\u2019s Excellence Strategy\u2014CECAD, EXC 2030\u2014390661388 and has received research grants from Actelion, Amplyx, Astellas, Basilea, Cidara, Da Volterra, F2G, Gilead, Janssen, Medicines Company, Melinta, Merck\/MSD, Octapharma, Pfizer, Scynexis, is a consultant to Actelion, Allecra, Amplyx, Astellas, Basilea, Biosys, Cidara, Da Volterra, Entasis, F2G, Gilead, Matinas, MedPace, Menarini, Merck\/MSD, Mylan, Nabriva, Noxxon, Octapharma, Paratek, Pfizer, PSI, Roche Diagnostics, Scynexis, and Shionogi, and received lecture honoraria from Al-Jazeera Pharmaceuticals, Astellas, Basilea, Gilead, Grupo Biotoscana, Merck\/MSD and Pfizer. L.M.B. has received lecture honoraria from Astellas and Merck\/MSD, and travel grants from 3M and Gilead. OB received speaker fees and\/or travel grants from Pfizer, MSD, Roche and Sanofi and has been a consultant to bioM\u00e9rieux and Mylan. F.M. is a consultant for Da Volterra, IPSEN, Servier and received research grants from Da Volterra, Sanofi and Servier. MJGTV has received research grants from 3M, Astellas Pharma, Da Volterra, Gilead Sciences, Glycom, MaaT Pharma, Merck\/MSD, Organobalance, Seres Therapeutics; speaker fees from Astellas Pharma, Basilea, Gilead Sciences, Merck\/MSD, Organobalance, Pfizer and has been a consultant to Alb Fils Kliniken GmbH, Astellas Pharma, Bio-M\u00e9rieux, Da Volterra, Ferring, MaaT Pharma, Merck\/MSD. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2240"}}